Novo Nordisk has outlined a long-term strategy that includes launching five blockbuster drugs by 2030 and generating $23 billion in pipeline revenue by 2035 to offset potential sales erosion after Wegovy’s patent expiry. The plan hinges on a new wave of weight-loss tablets and improved combinations of diabetes and obesity treatments aimed at greater weight loss with fewer side effects. It also includes an expansion into areas such as blood and endocrine disorders. Investors remained unconvinced, sending the shares down 8% on Monday.

International oil prices fell for a sixth straight session, with Brent down about 1% to $98.30 and WTI down 1.4% to $89.49. U.S.-Iran talks held at the United Nations, alongside the restart of a previously disrupted Saudi pipeline, eased concerns over potential Middle East supply disruptions. Saudi Aramco plans to restore pipeline flows to roughly 4 million barrels per day (bpd) within a few weeks.

A U.S. FDA advisory panel is set to vote on whether to recommend authorization of Grail’s Galleri blood test, which the company says can detect up to 50 types of cancer and costs $949. The test is under expedited FDA review, and an approval could make it the first FDA-authorized multicancer screening blood test and potentially open the door to insurance reimbursement. Abbott is also pursuing FDA clearance for a competing multicancer test.

Saudi Arabia has brought a 1,200-kilometre oil pipeline back into operation, allowing crude to be shipped directly to the Red Sea and bypass the Strait of Hormuz. The move eased concerns about supply disruptions. Global oil prices at one point fell by more than US$2 a barrel on Tuesday.

SAP reported Q2 2026 results led by €6.28B ($7.15B USD) Cloud Revenue Growing 22%, and SAP shares moved -1.59% in the completed reaction session. The analysis explains the earnings mix, financial outlook and three-month technical levels.

Ferrari reported Q2 2026 results led by €1.94B ($2.23B USD) Revenue and €755M ($866.4M USD) EBITDA, and RACE shares moved +3.12% in the completed reaction session. The analysis explains the earnings mix, financial outlook and three-month technical levels.

Grab shares slid to a more than three-year low of $2.74 after the company announced an acquisition of Atome Financial. The company also unveiled a plan to buy back about $900 million of shares over the next 12 months, but the announcement did not lift the stock. Chief executive Anthony Tan and president Alex Hungate then bought more than $30.86 million of Grab shares combined. After the purchases were disclosed, Grab shares closed up 8.9% the next day.

QuantumScape reported Q2 2026 results led by $64.2M Adjusted EBITDA Loss, and QS shares moved -12.95% in the completed reaction session. The analysis explains the earnings mix, financial outlook and three-month technical levels.